Singapore markets close in 7 hours 53 minutes

Straits Times Index
3,365.67
-12.62(-0.37%)
Nikkei
27,505.75
+178.64(+0.65%)
Hang Seng
21,842.33
-227.40(-1.03%)
FTSE 100
7,771.70
-13.17(-0.17%)
BTC-USD
23,100.54
+256.65(+1.12%)
CMC Crypto 200
524.33
+5.54(+1.07%)

Bristol-Myers Squibb Company (BMY)

NYSE - NYSE Delayed Price. Currency in USD

Add to watchlist

72.65

+0.62

(+0.86%)

At close: 04:00PM EST

72.38

-0.27

(-0.37%)

After hours:

07:55PM EST

Trade prices are not sourced from all markets

Press Releases

Business Wire
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia
PRINCETON N.J., January 27, 2023--BMS Receives Positive CHMP Opinion for Reblozyl® for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia
Business Wire
Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
PRINCETON, N.J., January 27, 2023--BMS Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Business Wire
Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
PRINCETON, N.J., January 26, 2023--BMS Announces TRANSCEND CLL 004 Trial of Breyanzi Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory CLL